Abcuro has raised $155 million in an oversubscribed second financing round that will fund its phase 2/3 trial of lead drug ABC008 for the treatment of inclusion body myosi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.